Concepts (267)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 33 | 2018 | 1393 | 1.590 |
Why?
|
| Dobutamine | 15 | 2018 | 71 | 1.050 |
Why?
|
| Ventricular Function, Left | 17 | 2016 | 287 | 1.020 |
Why?
|
| Magnetic Resonance Imaging, Cine | 10 | 2016 | 109 | 0.730 |
Why?
|
| Ventricular Dysfunction, Left | 10 | 2016 | 184 | 0.720 |
Why?
|
| Anthracyclines | 6 | 2016 | 62 | 0.610 |
Why?
|
| Myocardial Contraction | 6 | 2015 | 66 | 0.600 |
Why?
|
| Stroke Volume | 11 | 2016 | 440 | 0.500 |
Why?
|
| Exercise Test | 9 | 2015 | 247 | 0.450 |
Why?
|
| Cardiotonic Agents | 7 | 2015 | 52 | 0.430 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2016 | 75 | 0.390 |
Why?
|
| Myocardial Ischemia | 5 | 2018 | 114 | 0.390 |
Why?
|
| Coronary Vessels | 3 | 2010 | 180 | 0.370 |
Why?
|
| Models, Cardiovascular | 2 | 2010 | 33 | 0.370 |
Why?
|
| Music Therapy | 2 | 2008 | 8 | 0.360 |
Why?
|
| Heart Failure | 9 | 2015 | 780 | 0.340 |
Why?
|
| Predictive Value of Tests | 17 | 2018 | 939 | 0.340 |
Why?
|
| Middle Aged | 42 | 2018 | 12726 | 0.340 |
Why?
|
| Myocardial Perfusion Imaging | 3 | 2016 | 27 | 0.330 |
Why?
|
| Image Enhancement | 1 | 2010 | 74 | 0.310 |
Why?
|
| Aged | 34 | 2020 | 11022 | 0.300 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2016 | 260 | 0.300 |
Why?
|
| Heart Ventricles | 4 | 2016 | 155 | 0.290 |
Why?
|
| Infant Care | 1 | 2008 | 3 | 0.290 |
Why?
|
| Humans | 55 | 2020 | 34562 | 0.290 |
Why?
|
| Chest Pain | 4 | 2011 | 232 | 0.280 |
Why?
|
| Infant, Premature | 1 | 2008 | 80 | 0.280 |
Why?
|
| Female | 45 | 2018 | 21532 | 0.280 |
Why?
|
| Weight Gain | 1 | 2008 | 117 | 0.270 |
Why?
|
| Emergency Service, Hospital | 4 | 2013 | 502 | 0.270 |
Why?
|
| Male | 43 | 2018 | 20740 | 0.270 |
Why?
|
| Myocardial Infarction | 8 | 2015 | 515 | 0.270 |
Why?
|
| Cardiovascular Diseases | 5 | 2014 | 1209 | 0.260 |
Why?
|
| Risk Factors | 18 | 2018 | 4137 | 0.250 |
Why?
|
| Echocardiography, Stress | 4 | 2016 | 28 | 0.220 |
Why?
|
| Myocardium | 6 | 2016 | 199 | 0.220 |
Why?
|
| Prospective Studies | 14 | 2020 | 2463 | 0.210 |
Why?
|
| Ventricular Remodeling | 3 | 2016 | 69 | 0.210 |
Why?
|
| Heart Diseases | 4 | 2011 | 124 | 0.210 |
Why?
|
| Aged, 80 and over | 16 | 2018 | 4157 | 0.210 |
Why?
|
| Time Factors | 12 | 2018 | 2353 | 0.200 |
Why?
|
| Coronary Circulation | 3 | 2016 | 44 | 0.200 |
Why?
|
| Contrast Media | 6 | 2015 | 149 | 0.190 |
Why?
|
| Cardiomyopathies | 2 | 2016 | 70 | 0.190 |
Why?
|
| Aging | 5 | 2020 | 1010 | 0.190 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2013 | 60 | 0.190 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2016 | 124 | 0.190 |
Why?
|
| Heptanoic Acids | 2 | 2014 | 35 | 0.190 |
Why?
|
| Pyrroles | 2 | 2014 | 62 | 0.180 |
Why?
|
| Acute Coronary Syndrome | 3 | 2013 | 210 | 0.180 |
Why?
|
| Blood Flow Velocity | 4 | 2011 | 87 | 0.180 |
Why?
|
| Prognosis | 10 | 2018 | 1606 | 0.170 |
Why?
|
| Organometallic Compounds | 3 | 2010 | 23 | 0.170 |
Why?
|
| Adult | 19 | 2020 | 10030 | 0.170 |
Why?
|
| Leukemia | 2 | 2013 | 44 | 0.160 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 628 | 0.160 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2020 | 115 | 0.150 |
Why?
|
| Edema, Cardiac | 2 | 2016 | 14 | 0.150 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2014 | 79 | 0.140 |
Why?
|
| Risk Assessment | 9 | 2018 | 1508 | 0.140 |
Why?
|
| Vasodilator Agents | 3 | 2014 | 69 | 0.130 |
Why?
|
| Aorta | 3 | 2009 | 139 | 0.130 |
Why?
|
| Muscle, Skeletal | 2 | 2020 | 575 | 0.130 |
Why?
|
| Breast Neoplasms | 2 | 2014 | 806 | 0.130 |
Why?
|
| Aortic Diseases | 2 | 2011 | 67 | 0.130 |
Why?
|
| Severity of Illness Index | 4 | 2015 | 922 | 0.130 |
Why?
|
| Sex Factors | 2 | 2016 | 708 | 0.130 |
Why?
|
| Adiposity | 2 | 2016 | 204 | 0.130 |
Why?
|
| Phantoms, Imaging | 2 | 2010 | 73 | 0.120 |
Why?
|
| Age Factors | 6 | 2018 | 1262 | 0.120 |
Why?
|
| Reproducibility of Results | 7 | 2015 | 823 | 0.120 |
Why?
|
| Patient Positioning | 1 | 2015 | 23 | 0.120 |
Why?
|
| Stress, Physiological | 2 | 2016 | 60 | 0.120 |
Why?
|
| Exercise Tolerance | 2 | 2009 | 140 | 0.110 |
Why?
|
| Intra-Abdominal Fat | 2 | 2016 | 67 | 0.110 |
Why?
|
| Survivors | 1 | 2016 | 177 | 0.110 |
Why?
|
| Simvastatin | 1 | 2014 | 28 | 0.110 |
Why?
|
| Tubulin Modulators | 1 | 2014 | 10 | 0.110 |
Why?
|
| Heart Rate | 4 | 2011 | 372 | 0.110 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 40 | 0.110 |
Why?
|
| North Carolina | 6 | 2015 | 1613 | 0.100 |
Why?
|
| Renal Circulation | 1 | 2014 | 13 | 0.100 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2014 | 13 | 0.100 |
Why?
|
| Furosemide | 1 | 2014 | 9 | 0.100 |
Why?
|
| Prediabetic State | 1 | 2015 | 79 | 0.100 |
Why?
|
| Renal Artery | 1 | 2014 | 50 | 0.100 |
Why?
|
| Renal Artery Obstruction | 1 | 2014 | 42 | 0.100 |
Why?
|
| Polysomnography | 1 | 2013 | 41 | 0.100 |
Why?
|
| Manometry | 1 | 2013 | 24 | 0.100 |
Why?
|
| Aorta, Thoracic | 2 | 2011 | 87 | 0.100 |
Why?
|
| Coronary Artery Disease | 2 | 2015 | 441 | 0.100 |
Why?
|
| Angina Pectoris | 1 | 2013 | 24 | 0.100 |
Why?
|
| Cardiology Service, Hospital | 1 | 2013 | 23 | 0.100 |
Why?
|
| Oxygen | 1 | 2014 | 152 | 0.100 |
Why?
|
| Disability Evaluation | 1 | 2014 | 262 | 0.100 |
Why?
|
| Lymphoma | 1 | 2013 | 40 | 0.100 |
Why?
|
| Heterocyclic Compounds | 2 | 2010 | 16 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 168 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 271 | 0.090 |
Why?
|
| Cardiac Output | 2 | 2009 | 37 | 0.090 |
Why?
|
| Adenoidectomy | 1 | 2012 | 3 | 0.090 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2012 | 3 | 0.090 |
Why?
|
| Tonsillectomy | 1 | 2012 | 12 | 0.090 |
Why?
|
| Esophageal pH Monitoring | 1 | 2012 | 4 | 0.090 |
Why?
|
| Sodium Chloride | 1 | 2012 | 26 | 0.090 |
Why?
|
| Rhinitis | 1 | 2012 | 10 | 0.090 |
Why?
|
| Sinusitis | 1 | 2012 | 16 | 0.090 |
Why?
|
| Atrial Function, Left | 1 | 2012 | 23 | 0.090 |
Why?
|
| Ventricular Function, Right | 1 | 2011 | 20 | 0.090 |
Why?
|
| Arteries | 2 | 2013 | 83 | 0.090 |
Why?
|
| Hospital Costs | 1 | 2011 | 51 | 0.080 |
Why?
|
| Health Expenditures | 1 | 2011 | 71 | 0.080 |
Why?
|
| Pulmonary Edema | 1 | 2011 | 13 | 0.080 |
Why?
|
| Perfusion Imaging | 1 | 2011 | 8 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 104 | 0.080 |
Why?
|
| Patient Admission | 1 | 2011 | 59 | 0.080 |
Why?
|
| Inpatients | 1 | 2011 | 88 | 0.080 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2010 | 12 | 0.080 |
Why?
|
| Pulsatile Flow | 1 | 2010 | 25 | 0.080 |
Why?
|
| Abdominal Fat | 1 | 2010 | 52 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2014 | 3623 | 0.080 |
Why?
|
| Cerebrovascular Circulation | 1 | 2011 | 104 | 0.080 |
Why?
|
| Coronary Stenosis | 2 | 2016 | 31 | 0.080 |
Why?
|
| Doxorubicin | 1 | 2010 | 92 | 0.080 |
Why?
|
| Bicycling | 1 | 2009 | 14 | 0.080 |
Why?
|
| Delivery of Health Care | 1 | 2011 | 176 | 0.080 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2009 | 36 | 0.080 |
Why?
|
| Meglumine | 1 | 2009 | 4 | 0.080 |
Why?
|
| Gadolinium DTPA | 1 | 2009 | 16 | 0.070 |
Why?
|
| Computer Simulation | 1 | 2010 | 256 | 0.070 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 614 | 0.070 |
Why?
|
| Women's Health Services | 1 | 2009 | 12 | 0.070 |
Why?
|
| Atropine | 4 | 2011 | 23 | 0.070 |
Why?
|
| Therapeutic Touch | 1 | 2009 | 10 | 0.070 |
Why?
|
| Sucking Behavior | 1 | 2008 | 4 | 0.070 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2010 | 159 | 0.070 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2008 | 11 | 0.070 |
Why?
|
| Infant Behavior | 1 | 2008 | 9 | 0.070 |
Why?
|
| Single-Blind Method | 3 | 2020 | 214 | 0.070 |
Why?
|
| Endothelium, Vascular | 2 | 2016 | 163 | 0.070 |
Why?
|
| Lower Extremity | 1 | 2009 | 106 | 0.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2009 | 46 | 0.070 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2010 | 222 | 0.070 |
Why?
|
| Proportional Hazards Models | 4 | 2013 | 804 | 0.070 |
Why?
|
| Outpatients | 1 | 2008 | 61 | 0.070 |
Why?
|
| Angina, Unstable | 3 | 2015 | 22 | 0.070 |
Why?
|
| Adipose Tissue | 1 | 2010 | 366 | 0.070 |
Why?
|
| Heart Valve Diseases | 1 | 2007 | 31 | 0.060 |
Why?
|
| Heart Defects, Congenital | 1 | 2007 | 38 | 0.060 |
Why?
|
| Kidney | 1 | 2010 | 528 | 0.060 |
Why?
|
| Stress, Psychological | 1 | 2008 | 233 | 0.060 |
Why?
|
| Leg | 1 | 2006 | 71 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2008 | 730 | 0.060 |
Why?
|
| Hospitalization | 3 | 2018 | 500 | 0.060 |
Why?
|
| Linear Models | 3 | 2012 | 465 | 0.060 |
Why?
|
| Fibrosis | 2 | 2016 | 131 | 0.060 |
Why?
|
| Costs and Cost Analysis | 2 | 2020 | 113 | 0.060 |
Why?
|
| Disease Progression | 2 | 2018 | 634 | 0.060 |
Why?
|
| Electrocardiography | 4 | 2013 | 657 | 0.060 |
Why?
|
| Observer Variation | 3 | 2012 | 110 | 0.050 |
Why?
|
| Echocardiography | 3 | 2011 | 202 | 0.050 |
Why?
|
| Cross-Sectional Studies | 3 | 2016 | 1607 | 0.050 |
Why?
|
| Hypertension | 1 | 2010 | 1024 | 0.050 |
Why?
|
| Child | 4 | 2012 | 2614 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2009 | 926 | 0.050 |
Why?
|
| Intraoperative Complications | 1 | 2002 | 62 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2015 | 508 | 0.040 |
Why?
|
| Length of Stay | 2 | 2013 | 335 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 803 | 0.040 |
Why?
|
| Exercise | 1 | 2006 | 701 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 2020 | 19 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 305 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2020 | 100 | 0.040 |
Why?
|
| Education, Distance | 1 | 2020 | 19 | 0.040 |
Why?
|
| Myosin Heavy Chains | 1 | 2020 | 89 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2012 | 597 | 0.040 |
Why?
|
| Oxygen Consumption | 2 | 2015 | 167 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2011 | 2367 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2012 | 110 | 0.040 |
Why?
|
| Regional Blood Flow | 2 | 2009 | 95 | 0.040 |
Why?
|
| Gadolinium | 2 | 2010 | 22 | 0.030 |
Why?
|
| Adenosine | 2 | 2011 | 74 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2016 | 35 | 0.030 |
Why?
|
| Femoral Artery | 2 | 2009 | 50 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2009 | 111 | 0.030 |
Why?
|
| Microcirculation | 1 | 2016 | 72 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2015 | 3825 | 0.030 |
Why?
|
| Young Adult | 2 | 2013 | 2831 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 703 | 0.030 |
Why?
|
| Comorbidity | 1 | 2016 | 596 | 0.030 |
Why?
|
| Infant | 2 | 2008 | 1123 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 261 | 0.030 |
Why?
|
| Vasodilation | 2 | 2006 | 96 | 0.030 |
Why?
|
| Brachial Artery | 1 | 2014 | 76 | 0.030 |
Why?
|
| Equipment Safety | 1 | 2013 | 21 | 0.030 |
Why?
|
| Systole | 2 | 2005 | 103 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 213 | 0.020 |
Why?
|
| Observation | 1 | 2013 | 25 | 0.020 |
Why?
|
| Troponin I | 1 | 2013 | 25 | 0.020 |
Why?
|
| Equipment Design | 1 | 2013 | 192 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 306 | 0.020 |
Why?
|
| Myocardial Revascularization | 1 | 2013 | 42 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 267 | 0.020 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2013 | 89 | 0.020 |
Why?
|
| Mobility Limitation | 1 | 2014 | 222 | 0.020 |
Why?
|
| Troponin | 1 | 2013 | 114 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2015 | 529 | 0.020 |
Why?
|
| Gastric Acidity Determination | 1 | 2012 | 4 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 2012 | 36 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2011 | 30 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2013 | 141 | 0.020 |
Why?
|
| Laryngoscopy | 1 | 2012 | 41 | 0.020 |
Why?
|
| Survival Rate | 1 | 2014 | 928 | 0.020 |
Why?
|
| Models, Economic | 1 | 2011 | 21 | 0.020 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2011 | 15 | 0.020 |
Why?
|
| Cost Savings | 1 | 2011 | 39 | 0.020 |
Why?
|
| Drug Costs | 1 | 2011 | 51 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 1034 | 0.020 |
Why?
|
| Spin Labels | 1 | 2011 | 27 | 0.020 |
Why?
|
| Reference Standards | 1 | 2011 | 34 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2011 | 47 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 1290 | 0.020 |
Why?
|
| Diastole | 1 | 2011 | 100 | 0.020 |
Why?
|
| Acute Disease | 1 | 2011 | 277 | 0.020 |
Why?
|
| Self Administration | 1 | 2012 | 386 | 0.020 |
Why?
|
| Heart | 1 | 2011 | 191 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2010 | 62 | 0.020 |
Why?
|
| Software | 1 | 2011 | 130 | 0.020 |
Why?
|
| Medroxyprogesterone | 1 | 2010 | 15 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2010 | 29 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2011 | 214 | 0.020 |
Why?
|
| Adolescent | 2 | 2008 | 3805 | 0.020 |
Why?
|
| Iliac Artery | 1 | 2009 | 55 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 318 | 0.020 |
Why?
|
| Muscle Contraction | 1 | 2009 | 183 | 0.020 |
Why?
|
| Body Composition | 1 | 2010 | 415 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2012 | 954 | 0.020 |
Why?
|
| Obesity | 1 | 2016 | 1246 | 0.020 |
Why?
|
| Affect | 1 | 2008 | 72 | 0.020 |
Why?
|
| United States | 1 | 2016 | 4278 | 0.020 |
Why?
|
| Postmenopause | 1 | 2010 | 461 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2008 | 168 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2010 | 379 | 0.020 |
Why?
|
| Neoplasms | 1 | 2014 | 793 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2009 | 385 | 0.020 |
Why?
|
| Quality of Life | 1 | 2013 | 1032 | 0.020 |
Why?
|
| Transplants | 1 | 2007 | 24 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2011 | 1910 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2009 | 585 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 988 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 1129 | 0.020 |
Why?
|
| Reference Values | 1 | 2006 | 265 | 0.020 |
Why?
|
| Rest | 1 | 2006 | 53 | 0.010 |
Why?
|
| Rats | 1 | 2010 | 1946 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2008 | 1355 | 0.010 |
Why?
|
| Ergometry | 1 | 2002 | 5 | 0.010 |
Why?
|
| Thigh | 1 | 2003 | 43 | 0.010 |
Why?
|
| Heart Function Tests | 1 | 2002 | 10 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 2003 | 168 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2003 | 323 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2006 | 901 | 0.010 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2002 | 73 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2002 | 354 | 0.010 |
Why?
|
| Radiography | 1 | 2003 | 397 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2002 | 480 | 0.010 |
Why?
|
| Algorithms | 1 | 2003 | 561 | 0.010 |
Why?
|
| Animals | 1 | 2010 | 8579 | 0.010 |
Why?
|